BLIS K-12 & M-18: Benefits, Dosage, Side Effects & Research (2026)
Last Updated: April 2026 | Reviewed by BioBoost Research Team
What Are BLIS K-12 and BLIS M-18?
BLIS K-12 and BLIS M-18 are two strains of Streptococcus salivarius — a bacterial species naturally present in the healthy human mouth. “BLIS” stands for Bacteriocin-Like Inhibitory Substances, which are the antimicrobial compounds these strains produce to defend their territory against harmful bacteria.
Unlike gut probiotics (Lactobacillus acidophilus, Bifidobacterium), which are optimized for intestinal survival, BLIS strains are native to the oral environment. They evolved in the mouth, they colonize the mouth, and their mechanisms of action are entirely specific to oral health — making them arguably the most relevant probiotics available for dental and throat health.
Both strains were isolated and developed by Professor John Tagg at the University of Otago, New Zealand, who has spent over 40 years studying oral streptococci. BLIS Technologies, founded on this research, has conducted numerous clinical trials on both strains.
How Do BLIS K-12 and M-18 Work?
BLIS K-12 and M-18 work through a mechanism called competitive exclusion: they colonize the same surfaces in the mouth that harmful bacteria occupy, physically displacing them. Once established, they produce bacteriocin-like inhibitory substances that directly kill competing pathogens.
BLIS K-12 targets: The tongue dorsum and tonsillar crypts — areas where Streptococcus pyogenes (strep throat), volatile sulfur compound (VSC)-producing bacteria, and pathogens causing tonsillitis reside. K-12 produces Salivaricin A and Salivaricin B, two well-characterized bacteriocins.
BLIS M-18 targets: Tooth surfaces and gingival crevices — where Streptococcus mutans (the primary cavity-causing bacterium) forms biofilm. M-18 produces Salivaricin M, which specifically inhibits S. mutans colonization and biofilm formation.
Proven Benefits — Evidence-Based
🟢 BLIS K-12: Halitosis (Bad Breath) — STRONG EVIDENCE
Multiple clinical trials have demonstrated BLIS K-12’s effectiveness against chronic bad breath. A landmark 2005 study by Ouwehand et al. showed that K-12 supplementation for 3 weeks significantly reduced VSC levels in participants with chronic halitosis. A follow-up study demonstrated >85% of participants maintained reduced VSC production at 30-day follow-up. The mechanism is direct displacement of VSC-producing tongue bacteria. Dosage studied: ~10⁹ CFU/day.
🟢 BLIS K-12: ENT Infections (Tonsillitis, Strep) — STRONG EVIDENCE
A New Zealand clinical trial (Di Pierro et al., 2012) found that children supplementing with BLIS K-12 for 90 days had a 90% reduction in recurrent streptococcal pharyngotonsillitis compared to controls. An Italian study of 64 children showed similar results — K-12 reduced strep throat episodes significantly over a 3-month period. These are among the most robust findings in oral probiotic research. Dosage studied: 10⁹ CFU/day.
🟢 BLIS K-12: Otitis Media (Ear Infections) — STRONG EVIDENCE
A double-blind RCT found BLIS K-12 reduced acute otitis media episodes in children prone to recurrent ear infections. The mechanism involves K-12 colonizing the nasopharynx and preventing pathogenic bacteria from ascending to the middle ear via the Eustachian tube.
🟡 BLIS M-18: Cavity Prevention (S. mutans Inhibition) — MODERATE EVIDENCE
A 2014 study by Caglar et al. found that BLIS M-18 supplementation in school-age children for 3 months significantly reduced salivary S. mutans counts compared to placebo. The mechanism is competitive displacement on tooth surfaces and Salivaricin M production that inhibits S. mutans biofilm. More large-scale adult trials are needed. Dosage studied: 10⁸ CFU/day.
🟡 BLIS M-18: Plaque Reduction — MODERATE EVIDENCE
Early clinical data suggests BLIS M-18 may reduce dental plaque formation by disrupting the early colonization phase of plaque biofilm. This is mechanistically coherent — if S. mutans cannot establish itself, the cascade of events leading to plaque and caries is interrupted at its root.
Key Studies & Evidence Summary
| Study | Year | Strain | Participants | Duration | Key Finding |
|---|---|---|---|---|---|
| Ouwehand et al. | 2005 | K-12 | 23 adults | 3 weeks | Significant VSC reduction; halitosis improvement |
| Di Pierro et al. | 2012 | K-12 | 66 children | 90 days | 90% reduction in streptococcal tonsillitis episodes |
| Caglar et al. | 2014 | M-18 | 60 children | 3 months | Significant S. mutans count reduction in saliva |
| Burton et al. | 2006 | K-12 | 56 adults | 4 weeks | Significant reduction in oral pathogen populations |
| Wescombe et al. | 2012 | K-12 + M-18 | Review | N/A | Comprehensive safety and efficacy review — both strains safe for long-term use |
Recommended Dosage
BLIS K-12: 10⁹ CFU/day (1 billion CFU) based on clinical trials for ENT and halitosis applications. Studies typically used once-daily dosing in slow-dissolving lozenge or chewable tablet form.
BLIS M-18: 10⁸ CFU/day (100 million CFU) based on the most-cited dental trials. Lower effective dose compared to K-12.
Delivery format: Chewable tablet or slow-dissolving lozenge — NOT standard capsules. Direct oral contact is essential for colonization. Swallowing a capsule means stomach acid destroys the strains before they reach the mouth tissue.
Duration: Studies typically ran 3–12 weeks. For ongoing oral health maintenance, continuous daily use appears safe based on long-term safety reviews.
Side Effects & Safety
BLIS K-12 and M-18 have an excellent safety profile. They are native human oral bacteria — not foreign organisms being introduced to a new environment. Wescombe et al. (2012) conducted a comprehensive safety review and found no adverse effects in clinical trial participants. Both strains are classified as GRAS (Generally Recognized As Safe) by regulatory standards.
The only population requiring caution is severely immunocompromised individuals (active chemotherapy, organ transplant patients on high-dose immunosuppressants), for whom any live bacterial supplement should be discussed with a physician first.
Drug Interactions
No significant drug interactions have been documented for BLIS K-12 or M-18. However, concurrent antibiotic use will kill these strains — do not use BLIS supplements simultaneously with antibiotics. Resume supplementation 48–72 hours after completing any antibiotic course.
Products Containing BLIS K-12 and/or M-18
Based on our dental supplement analysis, the following products contain one or both BLIS strains:
- GumAktiv — Contains K-12 + M-18 + L. reuteri + L. paracasei. Read full review →
- ProDentim — Contains K-12 + M-18 + 3 additional strains. Read full review →
- Synadentix — Probiotic blend (specific strains not fully disclosed). Read full review →
Frequently Asked Questions
Is BLIS K-12 the same as a regular probiotic?
No. Most consumer probiotics contain gut strains (L. acidophilus, Bifidobacterium) designed to survive stomach acid and colonize intestinal tissue. BLIS K-12 is a native oral bacterium designed to colonize the mouth, tongue, and throat. The biology, mechanism, and target application are completely different.
How long does it take for BLIS K-12 to work for bad breath?
Clinical studies show VSC reduction beginning within 1–2 weeks, with statistically significant improvements at 3 weeks. Maintaining daily supplementation sustains the effect — some studies followed participants for 30 days post-supplementation and found continued benefit, suggesting K-12 can establish stable colonization.
Can children take BLIS probiotics?
Yes — several major clinical trials were conducted specifically in children (ages 3–12) for ENT and dental applications. Both strains showed excellent safety in pediatric populations. Use age-appropriate dosing forms.
Do I need both K-12 and M-18, or is one sufficient?
It depends on your primary concern. K-12 alone is sufficient for bad breath and ENT health. M-18 alone provides tooth-specific cavity protection. If you want comprehensive oral coverage, a supplement containing both — like GumAktiv or ProDentim — is the most logical choice.
Can BLIS supplements replace dental treatment?
No. BLIS K-12 and M-18 are preventive and supportive tools — they reduce the bacterial burden that causes dental problems, but they cannot reverse existing cavities, treat active periodontal disease, or substitute for professional dental care. Use them as part of a complete oral health strategy.
References
- Ouwehand AC, et al. (2005). The effect of S. salivarius K-12 on oral malodor. Oral Diseases.
- Di Pierro F, et al. (2012). Use of Streptococcus salivarius K-12 in the prevention of streptococcal pharyngotonsillitis in children. Drug, Healthcare and Patient Safety.
- Caglar E, et al. (2014). Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. Clinical Oral Investigations.
- Wescombe PA, et al. (2012). Developing oral probiotic products for long-term human use. Cellular and Molecular Life Sciences.
- Burton JP, et al. (2006). A preliminary study of the effect of probiotic Streptococcus salivarius K-12 on oral bacterial flora. Journal of Applied Microbiology.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement regimen.
